| Literature DB >> 34041399 |
Shashank M Patil1, Ramith Ramu1, Prithvi S Shirahatti2, Chandan Shivamallu1, Raghavendra G Amachawadi3.
Abstract
Thymus vulgaris Linn. is a medicinal and culinary herb from the Southern European region known for its anti-infective, cardioprotective, gastroprotective, anti-inflammatory, and immunomodulatory activities since the Egyptian era. The reported pharmacological activities of T. vulgaris L. include antibacterial, antioxidant, anti-inflammatory, antiviral, and anti-cancerous activities. In this review, a comprehensive approach is put forth to scrutinize and report the available data on phytochemistry, ethnopharmacology, pharmacology, and toxicology of the plant. The different extracts and essential oil obtained from the plant have been assessed and reported to treat ailments like microbial infections, inflammation, non-communicable diseases like cancer, and sexually transmitted diseases like HIV-1 and Herpes. The literature review has also indicated the use of volatile oils, phenolic acids, terpenoids, flavonoids, saponins, steroids, tannins, alkaloids, and polysaccharides in pharmacotherapy. Applications of these compounds including antidiabetic, anti-Alzheimer's, cardio, neuro and hepatoprotective, anti-osteoporosis, sedative, immunomodulatory, antioxidant, anti-tyrosinase, antispasmodic, antinociceptive, gastroprotective, anticonvulsant, antihypertensive, antidepressant, anti-amnesia, and anti-helminthic activities have been mentioned. Further, based on research gaps, recommendations have been provided to evaluate T. vulgaris L. systematically to develop plant-based drugs, nutraceuticals, and to evaluate their clinical efficiency and safety.Entities:
Keywords: Ethnopharmacology; Pharmacology; Phytochemistry; Thymus vulgaris L.; Toxicology
Year: 2021 PMID: 34041399 PMCID: PMC8141878 DOI: 10.1016/j.heliyon.2021.e07054
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1PRISMA outline followed for literature search.
Figure 2A) Plant B) flowers C) leaves D) seeds of Thymus vulgaris L.
Summary of the ethnomedicinal uses of Thymus vulgaris L.
| Ethnomedicinal Use | Part of the Plant | Palnt Material | Mode of Application | References |
|---|---|---|---|---|
| Treatment of poisoning | Aerial parts/stem/leaves | Dried whole plant/water extract | Oral, Topical | [ |
| Disinfection and wound healing | Aerial parts/stem/leaves | Dried whole plant/vapours, water extract | Topical | [ |
| Plague-blistered skin, Acne, oily skin, dermatitis | Aerial parts/stem/leaves | Water extract, volatile oil | Topical | [ |
| Treatment of foodborne illnesses | Aerial parts/stem/leaves | Dried whole plant/Water extract | Oral | [ |
| Asthma, bronchitis, whooping cough, pharyngitis | Aerial parts/stem/Leaves | Water extract | Oral | [ |
| Cough, cold and sore throat | Aerial parts/stem/Leaves/Flower shoots | Water extract | Oral | [ |
| Intestinal worms | Aerial parts/stem/Leaves | Dried whole plant/water extract | Oral | [ |
| Rheumatic aches, body pain and sciatica | Aerial parts/stem/Leaves | Volatile oil | Topical | [ |
| Emphysema, sedative, anthelmintic, antifungal, antispasmodic, diuretic | Not defined | Not defined | Not defined | [ |
| Skin infections, high blood pressure, heart problems, fluid retention, cystitis, digestive system disorders, rheumatism and arthritis | Flower shoots | Not defined | Not defined | [ |
Summary of the individually reported phytochemicals and their pharmacological significance present in Thymus vulgaris Linn.
| Class | Compound Name | IUPAC Name | Pharmacological Activity | Reference |
|---|---|---|---|---|
| Phenolic compounds | Quinic acid | 6-methoxyquinoline-4-carboxylic acid | Anti-cancer, immunomodulatory, anti-fungal, antioxidant, neuroprotective | [ |
| Rosmaric acid | (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl) prop-2-enoyl] oxypropanoic acid | Anti-alzheimer's, anti-cancer, antidiabetic, antimicrobial, cardioprotective, nephroprotective, anti-ageing, hepatoprotective, anti-inflammatory, anti-allergic, anti-depressant | [ | |
| Caffeic acid | (E)-3-(3,4-dihydroxyphenyl) prop-2-enoic acid | Antioxidant, antimicrobial, anticancer, adipogenetic, lipolytic, anti-alzheimer's, antiviral, antidiabetic, cardioprotective, hepatoprotective, anti-atherosclerotic | [ | |
| p-coumaric acid | (E)-3-(4-hydroxyphenyl) prop-2-enoic acid | Immunomodulatory, anti-inflammatory, antioxidant, gastroprotective, antidiabetic, anti-hyperlipidemia, anti-tyrosinase, anticancer, hepatoprotective | [ | |
| p-hydroxybenzoic acid | 4-hydroxybenzoic acid | Anticancer, antimicrobial, antiviral | [ | |
| Gentisic acid | 2,5-dihydroxybenzoic acid | Anticancer, antioxidant, antimicrobial, cardioprotective, antimicrobial, anti-inflammatory, analgesic, nephroprotective, hepatoprotective, neuroprotective, muscle relaxant | [ | |
| Syringic acid | 4-hydroxy-3,5-dimethoxybenzoic acid | Anticancer, antioxidant, antidiabetic, anti-inflammatory, neuroprotective, antimicrobial, antiendotoxic, hepatoprotective, anti-osteoporotic | [ | |
| Ferulic acid | (E)-3-(4-hydroxy-3-methoxyphenyl) prop-2-enoic acid | Anticancer, antidiabetic, antioxidant, cardioprotective, neuroprotective, anti-alzheimer's, | [ | |
| Terpenoids | Thymol | 5-methyl-2-propan-2-ylphenol | Antibacterial, antifungal, antispasmodic, antitussive, anxiolytic, neuroprotective, antihypertensive, antioxidant, antihyperlipidemic, anti-inflammatory, immunomodulatory, anti-cancerous, analgesic, growth promoting | [ |
| Carvacrol | 2-methyl-5-propan-2-ylphenol | Antimicrobial, antimutagenic, antitumor, analgesic, anti-inflammatory, antihepatotoxic, antiparasitic, antispasmodic, and hepatoprotective | [ | |
| Geraniol | (2E)-3,7-dimethylocta-2,6-dien-1-ol | Anti-cancerous, anti-inflammatory, antioxidant, hepatoprotective, antimicrobial, cardioprotective, antidiabetic, neuroprotective | [ | |
| Linalool | 3,7-dimethylocta-1,6-dien-3-ol | Sedative, antiviral, anti-inflammatory, antioxidant, anti-nociceptive, analgesic, anesthetic, antimicrobial, anxiolytic, anti-hyperlipidemic, antinoceptive, antidepressive, neuroprotective | [ | |
| ρ-Cymene | 1-methyl-4-propan-2-ylbenzene | Antimicrobial, antinociceptive and anti-inflammatory, antioxidant, anxiolytic, anticancer, vasorelaxant, immunomodulatory, antinoceptive | [ | |
| γ-terpinene | 1-methyl-4-propan-2-ylcyclohexa-1,4-diene | Antibacterial, antioxidant, anti-inflammatory, antinociceptive. | [ | |
| Limonene | 1-methyl-4-(1-methylethenyl)-cyclohexene | Antibacterial, antifungal, anti-inflammatory, antinociceptive, antioxidant, | [ | |
| β-Caryophyllene | (1R,4E,9S)-4,11,11-trimethyl-8-methylidenebicyclo [7.2.0] undec-4-ene | Antimicrobial, cardioprotective, hepatoprotective, gastroprotective, neuroprotective, nephroprotective, antioxidant, anti-inflammatory, immunomodulatory | [ | |
| β-Pinene | 6,6-dimethyl-2-methylidenebicyclo [3.1.1] heptane | Anti-cancerous, antimicrobial, antioxidant, anti-inflammatory, analgesic, cytogenetic, gastroprotective, anxiolytic, cytoprotective, anticonvulsant, neuroprotective | [ | |
| α-Terpineol | 2-(4-methylcyclohex-3-en-1-yl) propan-2-ol | Anti-cancerous, antioxidant, antinociceptive, anticonvoluscent, gastroprotective, cardioprotective, antihypertensive, sedative | [ | |
| Flavonoids | Apigenin | 5,7-dihydroxy-2-(4-hydroxyphenyl) chromen-4-one | Antidiabetic, anti-cancerous, antidepressive, anti-insomnia, anti-amnesia, anti-alzheimer's, antiviral | [ |
| Luteolin | 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one | Anti-alzheimer's, anti-cancerous | [ | |
| Cirsimaritin | 5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxychromen-4-one | Antioxidant, anti-inflammatory, antimicrobial, antidiabetic, anticancer, neuroprotective, cardiovascular, hepatoprotective | [ | |
| Xanthomicrol | 5-hydroxy-2-(4-hydroxyphenyl)-6,7,8-trimethoxychromen-4-one | Anti-inflammatory, anti-spasmodic, anti-platelet, anti-cancerous effects | [ |
Figure 3Phenolic compounds with pharmacological activity in Thymus vulgaris L.
Figure 4Terpenoids with pharmacological activity in Thymus vulgaris L.
Figure 5Flavonoids with pharmacological activity in Thymus vulgaris L.
Summary of the pharmacological properties of Thymus vulgaris L.
| Pharmacological Activity | Type of Study | Models used | Plant part/material | Type of extract/compound | Doses used | Controls | Possible/reported mechanisms | Results | References |
|---|---|---|---|---|---|---|---|---|---|
| Antibacterial activity | Aerial parts | Ethanol | 100 μl of 6.25–0.025% serial dilutions | Solvent ethanol | Not defined | MIC was observed as >6.25, 3.12,>6.25, 0.2, 0.39, 0.78 mm respectively at 100 μl concentration (p < 0.05). These bacteria showed mixed response towards antibiotics. | [ | ||
| Methicillin-resistant | Not defined | Methanol | 200 mg/ml per kg of body weight | Positive control-infected, negative control-normal mice, Antibiotics | Not defined | For the bacteria isolated from throat and lungs, MIC was found to be 2.93 and 3.83 CFU (log10)/ml, respectively (p < 0.05). | [ | ||
| Aerial parts | Essential oil | 100 μl of 1/20–1/200 v/v serial dilutions | Amoxicillin, cefotaxime | Not defined | MIC of 25.5 mm at 100 μl concentration, in accordance with amoxicillin (23.0 mm) and cefotaxime (15.0 mm) (p < 0.05). | [ | |||
| Dried plant | Essential oil | 5–0.0024 μl/ml. | Growth control (broth + microbe), negative control (broth + propylene glycol + microbe), sterility control (broth + test oil), positive control (broth + streptomycin + microbe) | Possible inhibition of bacterial adsorption and biofilm matrix formation | Biofilm inhibition at MIC/MBC 0.156/0.315 μl/ml by oil, thymol, and carvacrol. Oil reduced the metabolic activity by 9.6–70.5%, (p < 0.05). | [ | |||
| Not defined | Essential oil | 10 μl of 2.87–11.5 μg/ml | Cefotaxime | Not defined | A significant inhibition with 35–40 mm inhibition zone at 2.8–11.5 at μg/ml was observed for MDR variants, whereas cefotaxime showed MIC at 32 μg/mL concentration (p < 0.05) | [ | |||
| Leaves and branches | Essential oil | 100 μl oil of different concentrations | Not defined | Not defined | Minimum bactericidal concentration (MBC) was found to be 8% at 100 μl concentration | [ | |||
| Not defined | Essential oil | 100 μl of 1.25 to 0.01% (v/v) | Media + microbes + PBS | Not defined | MIC values ranging from 0.039% to 0.078% at dilutions 0.01–1.25% v/v (p < 0.05) | [ | |||
| Antioxidant activity | Antioxidant enzyme levels in rabbits | Not defined | Aqueous extract | 50 mg/kg of body weight | Water | Not defined | Levels of antioxidant enzymes catalase, glutathione, glutathione-S-transferase, and superoxide dismutase increased by 14.12%, 27.69%, 98.75% and 78.29%, respectively (p < 0.05) | [ | |
| Antioxidant enzyme levels in rats | Dried leaves | Aqueous extract | 500 mg/kg body weight | Paracetamol (200 mg/kg) | Not defined | Alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase content increased by 2 units/mL. In combination with paracetamol, the enzyme levels increased by 15–20 units/ml (p < 0.01) | [ | ||
| Radical scavenging activity using DPPH | Leaf and stem | Aqueous extract | 0.0125–3.0 mg/ml | Not defined | Polysaccharide biding with BSA brings out the radical scavenging | Radical free scavenging activity of 92.0% at the concentration of 1.5 mg/mL, in accordance with butylated hydroxyanisole (BHA-95.7%) and butylated hydroxytoluene (BHT-96.6%). | [ | ||
| FRAP, ABTS, and FIC | Not defined | Essential oil | 0.23–30 mg/ml | Not defined | Not defined | FRAP, FIC, ABTS assays showed IC50 values 12.69, 13.29, and 6.46 mg/ml respectively (p < 0.05) | [ | ||
| Primary and secondary lipid oxidation products in oil in water (O/W) emulsions through DPPH | Dry waste plant | Ethanolic extract | 100 μl of different concentrations | Not defined | Not defined | IC50 of 93 μg/ml compared to BHT (89 μg/mL) (p > 0.05) | [ | ||
| Antifungal activity | Not defined | Essential oil | 5,10,15,20,30% (v/v) | Media + Tween 20 | Not defined | Mycelial growth inhibition values were found to be ranging between 13.9 to 41.4 mm at 5% concentration with ED50 values ranging from 9.3-18.0% for all the species (p < 0.05) | [ | ||
| Clinical isolates of | Not defined | Essential oil | 0.005–2.5% (v/v) | Amphotericin B | Possible ergosterol binding | MIC and MFC were in the range of 0.04–22.9 mg/ml for all the isolates. Thyme oil reduced the fungal growth in the initial hours (4–8). It inhibited the growth with sorbitol at lower MIC (0.08 mg/ml) (p < 0.05) | [ | ||
| Not defined | Thymol | 32, 64, and 128 mg/l | Kanamycin (45 μg/ml), ampicillin (100 μg/mL), and streptomycin (100 μg/ml) | Enhancing pmk-1and sec-1 gene expressions, which in turn enhance p38 MAPK signalling pathway | Complete inhibition of fungi and biofilm at 64 mg/l and 128 mg/ml, compared to control used (p < 0.05). Growth reduction at 12 h, compared to control (36 h). Thymol enhances the expressions of pmk-1and sec-1 genes, in turn p38 MAPK signalling pathway | [ | |||
| Not defined | Essential oil | 0.07–10 mg/ml | FLC (0.06–128 μg/mL), ITC (0.0078–2 μg/ml), VRC (0.0078–32 μg/mL) | Possible membrane deterioration by thymol, Possible ergosterol binding | MIC and MFC were found to be in 0.56–1.12 mg/ml in accordance with controls. Thymol showed better activity 0.02–0.08 mg/ml (p < 0.05) | [ | |||
| Not defined | Essential oil vapour and liquid phases | 0, 1, 5, 10, and 20 μg/ml | Aflatoxin B | Downregulating of fungal development genes brlA, abaA, wetA and aflatoxin biosynthesis genes aflR, aflD, and aflK | Vapor and liquid phases reduced growth at 20 and 400 μg/ml, respectively. Thyme oil 10 μg/mL of reduced production of afltoxin by 97.0 and 56.4% through vapour and liquid phases, respectively. (p < 0.05). | [ | |||
| Anti-inflammatory activity | NO radical scavenging in murine macrophage cell line J774A.1 | Flowering tops | Aqueous extract | 8.5, 16, 50.4, 84 μg/ml | Dexamethasone | Possible cellular mechanisms of suppression of iNOS induction by flavonoids | Significant scavenging of NO radicals with 80.3% of the activity at 16 μg/ml concentration was observed in accordance with control (p < 0.05) | [ | |
| 5-lipoxygenease (5-LOX) production, lipopolysaccharide (LPS) induced TNF-α, IL-1β, and IL-8 secretions using THP-1 cells | Dried plant | Essential oil | 30 μl of different concentrations | α-bisabolol | Not defined | 5-LOX got inhibited at 0.005 μg/ml (IC50) of thyme oil, compared to α-bisabolol (0.049 μg/mL). TNF-α, IL-1β, and IL-8 got inhibited at 0.01 μg/ml. | [ | ||
| Mice with carrageenan-induced paw edema | Aerial parts and dried leaves | Essential oil | 100, 200 and 400 mg/kg | Tween 80 and diclofenac | Not defined | Paw thickness was found reducing at a dose of 400 mg/kg. Results were in accordance with both the controls Tween 80 and diclofenac (p < 0.001). Toxic level of thyme oil was found (4500 mg/kg), where sedation was observed at 5000 mg/kg. | [ | ||
| Mice with carrageenan-induced pleurisy | Leaves | Essential oil | 250, 500 and 750 mg/kg | Croton oil | Carvacrol may act by inhibiting cytokines and leukotrienes, and these mediators are likely not involved in the mechanism of action of thymol | All the concentrations reduced inflammatory exudates as well as migrated leucocytes in ear edema. Individual assessment showed thymol (34.2%) and carvacrol (47.3%) are attributable for the anti-inflammatory activity (p < 0.05) | [ | ||
| Anti-cancerous activity | MCF7 (breast adenocarcinoma), HCT15 (colon carcinoma), HeLa (cervical carcinoma), HepG2 (hepatocellular carcinoma), and NCI-H460 (non-small cell lung cancer) cell lines | Dried aerial parts | Essential oil | 10–100 μg/ml | Ellipticine (0.24–65.2 μg/ml) | Possible involvement of thymol in the stimulation of active proliferation of pulp fibroblasts | [ | ||
| THP-1 leukemia cell line | Not defined | Essential oil | 10–500 μg/ml | DMSO | Not defined | At a concentration of 100 μg/ml and >200 μg/ml, thyme oil prevented the proliferation of THP-1 leukemia cells | [ | ||
| H460 lung cancer cell line | Not defined | Hydroalcoholic extract | 0.04–0.6% | Glyceraldehyde 3-phosphate dehydrogenase | Possible interference in pro-inflammatory cytokines | H460 lung cancer cell line was found to be sensitive at 0.11% of hydroalcoholic extract (p < 0.05) and downregulated NF-κB p65 and NF-κB p52 proteins along with the reduction of IL-1β and IL-8 gene expression in LPS model | [ | ||
| Mammary carcinoma rat and 4T1 mouse models | Dried plant | Thyme powder | 50 mg/kg body weight | Untreated models | Possible interference with pro-inflammatory cytokines, Possible upregulation of caspase genes at epigenetic level | Thyme powder reduced the volume of 4T1 tumours by 85% at 1% concentration. In rat model, the same concentration decreased the tumour frequency by 53% (p < 0.05). Upregulation of caspase-2 and caspase-3 enzymes, along with bcl-2 and Bax proteins | [ | ||
| HL-60 acute promyelotic leukemia cell line, human peripheral blood mononuclear cell (PBMC) | Not defined | Thymol | 5, 25, 50, 75 and 100 μM for 24 h | Camptothecin (5 μM) | Apoptosis induced by thymol in HL-60 cells was associated with ROS production, increase in mitochondrial H2O2 production, decrease in Bcl-2 protein, increase in Bax protein levels, enhancing apoptosis inducing factor (AIF) in mitochondria and caspase activation | Thymol showed no cytotoxic effect on human peripheral blood mononuclear cell (PBMC) at 5 and 25μM concentrations. However, extensive cytotoxicity was observed at >50 μM, after 24 h | [ | ||
| Synthesized silver nanoparticles against T47D human breast cancer cells | Dried leaves | Silver nanoparticles and ethanol extract | 12.5–200 μg/ml | Untreated cells | Nanoparticles could trig- ger translocation of phosphatidylserine (PS) from the inner membrane indicating apoptosis pathway rather than necrosis | T47D cells showed high sensitivity towards nanoparticles (90%) compared to the extract (75%). T47D cells treated with nanoparticles showed 18.40% early and 0.69% late apoptosis with varying IC50 concentrations (12.5–100 μg/mL). Same was observed in case of plant extract, where 15.67% early and 1.70% late apoptosis was found (p < 0.05) | [ | ||
| Antiviral activity | Influenza virus | Not defined | Essential oil vapour and liquid phases | 3.12–100 μl/ml | Canova oil | Possible interaction with hemagglutinin (HA) | Liquid phase at 3.1 μl/ml concentration completely inhibited the viral growth, which was better than that of control used (canola oil). Significant inhibition of HA was observed. Also, 50% of the culture was reduced depicted as TC50 14.34 μl/ml (p < 0.05) | [ | |
| Herpes simplex virus (HSV) on RC-37 (African green monkey kidney cells) | Not defined | Essential oil | 10–750 μg/ml | Untreated cells | Not defined | Cytotoxicity ranged between 20 μg/ml for citral and 1250 μg/ml for 1,8-cineole. IC50 values for1,8-cineole was 1200 μg/ml. Thyme oil proved to reduce the viral load by >96%, whereas all monoterpenes by >80% (p < 0.05) | [ | ||
| HIV-1 in HeLa HL3T1 cell line | Not defined | Essential oil | 7.5–240 | Neomycin, cisplatin | Possible alteration in the structure of Tat/TAR-RNA complex | EMSA showed a notable inhibitory potential of oil (3–6 μg/ml), compared to the control in case of Tat/TAR-RNA complex inhibition. Reduction activity test against Tat-induced HIV-1 LTR transcription resulted in RT50 = 0,83 μg/ml, a notable inhibitory potential which reduced viral transcription to 52% (p < 0.05) | [ | ||
| HIV-1 subtype A in PBMC cell line | Dried plant | Methanol extract | 10, 100, 200, 800 and 1600 μg/ml | DMSO, Zidovudine | Not defined | The cytotoxicity value (CC50) on PBMC was found to be 200 μg/ml. Antiviral assay revealed EC50 value of >500 μg/ml. Mean fluorescent intensity (MFI) of the CD4+ expressions were found to be 22.72 in PBMC (p < 0.05) | [ | ||
| Antidiabetic activity | Inhibition of α-glucosidase and α-amylase enzymes | Not defined | Aqueous, methanol and ethanol extracts | 4, 8, 15, and 20 μg/ml | Acarbose | Not defined | Methanol extract resulted in maximum inhibition of α-glucosidase (IC50 4.35, 22.04, 30.77, 43.13), though less compared to Acarbose (IC50 16.11, 44.6, 53.03, 63.70). Similarly, α-amylase got reduced maximally by the same extract (IC50 6.39, 11.47, 17.01, 22.93), less compared to Acarbose (IC50 12.37, 25.16, 36.08, 44.97) | [ | |
| Anxiolytic activity | Elevated plus-maze (EPM) rat model | Dried plant | Aqueous extract | 50 mg/kg, 100 mg/kg, and 200 mg/kg | Saline fed groups | Possible relation with antioxidant activity of phytochemicals | The aqueous extract exhibited a significant increase in rat movement into the open arms at 100 mg/kg (p < 0.05) and 200 mg/kg (p < 0.01). | [ | |
| UV-protective activity | Human skin cells | Not defined | Aqueous extract, thymol | 1.82 μg/ml extract and 1 μg/ml thymol | Normal cells without UV treatment, but with extract treatment | Reduction of ROS induced DNA damage, Possible involvement of polyphenols in protectivity | Aqueous extract of thyme leaf (1.82 μg/ml) and thymol (1 μg/ml) reduced the release lactic acid dehydrogenase (LDH), in cultured skin cells treated with UV rays. Cell proliferation was observed in thyme pre-treated skin cells in accordance with control, along with the reduction in DNA damage (p < 0.01) | [ | |
| Anthelminthic activity | Eimeria spp. oocysts from Turkey fowls | Not defined | Essential oil | 0, 1, 2, 4, 8, 10, 20, 40, 80, and 800 mg/ml | Ammonia and diclazuril | Not defined | Thyme oil showed significant anti-helminthic activity against 4 species of | [ | |
| Anti-anti-alzheimer's activity | Acetylcholine esterase and nicotinic acetylcholine receptor in | Aerial parts and leaves | Essential oil | 10, 20, 40, 60, 80, and 100 ppm | 10% DMSO | Upregulation of unc-17, unc-50, and cho-1 genes by ρ-Cymene | Enhancement of the nicotinic acetylcholine receptor activity, upregulation of unc-17, unc-50, and cho-1 genes at 40 and 60 ppm ρ-Cymene was attributed for gene upregulation activity along with downregulating ace-1 and ace-2 at 20 and 100 ppm (p < 0.05). Thymol and γ-terpinene enhanced synaptic acetylcholine levels in combination (40 ppm) | [ | |
| Anti-osteoporotic activity | Rat model with low calcium intake | Dried leaves | Leaf powder | 5% w/w | Standard diet + normal calcium (Ca 0.5% w/w), standard diet + low calcium (Ca 0.1% w/w), Thyme powder (5% w/w) + low calcium (Ca 0.1% w/w) | Possible promotion of calcium resorption in the gut | Significant increase in the bone mass (2.93 g/kg), length 32.8 mm), and density (0.13 g/cm2), compared to low calcium diet control (2.46 g/kg, 32.2 mm, and 0.09 g/cm2, respectively) (p < 0.05) | [ | |
| Anti-pulpotomy activity | Formocresolpulpotomy in humans | Not defined | Ethanolic extract | Suitable consistency | Formocresol | Not defined | Thyme ethanolic extract along with zinc oxide reduced pain and tenderness, Enhanced bone and root resorption. Clinical and radiographic evaluations showed 94.4% and 88.2% success, respectively with no statistical significance compared to the control, formocresol 88.2% (p > 0.05) | [ |
Summary of clinical trials of T. vulgaris preparations.
| Pharmacological activity | Type of study | Models | Plant part/material | Type of Extract/compound | Doses | Controls | Mechanisms | Results | References |
|---|---|---|---|---|---|---|---|---|---|
| Adipogenetic and anti-aging | Humans | Leaves and flowers | ThymLec gel 2% prepared from leaf and flower extract (1.0%–3.0%) + water, propanediol, glycerine +5.0%–13.4%) lecithin (additive) + benzyl alcohol, potassium sorbate, tocopherol (preservatives) | 2 mg/cm2 of the facial skin applied with 2% concentration (20 mg/g w/w), gently spreading, twice a day (morning and evening). | Placebo (formulation containing the same vehicle of ThymLec gel) and Benchmark 2% | ThymLec topical application leads into the adipogenesis and lipid production, further augmenting cell volume and better remodelling of face oval features. ThymLec modulates the PPAR-γ signalling pathway, increasing adiponectin production and adipocyte lipid accumulation. | Reduction of area (7.0%), depth, and length (10.2%) of the perioral wrinkles on day 60, whereas benchmark produced a reduction of 5.4% and 7.5%, respectively in case of humans. Length of the nasolabial lines (8.9%), Crow's feet wrinkles' area (8.9%), breadth (3.9s%), and length (11.1%) were also decreased. Face oval remodelling evaluation resulted in the reduction of total face volume (4.9 fold) in comparison with benchmark on day 60. | [ | |
| Anti-dysmenorrhea | Humans | Not defined | Essential oil | 25 drops of essential oil | Ibuprofen, Placebo (Ibuprofen 200mg + oil 25 drops) | Anti-prostaglandin and antispasmodic activity of | Pain intensity mean values reached lowest point (6.57–1.14 VAS) in case of oil consumers' group in comparison with placebo (6.13–3.45) and ibuprofen (5.3–1.48) (p < 0.05). No significant results were obtained in case of bleeding control by both oil and placebo. Oil was able to reduce clinical symptoms like lower abdominal pain, nausea, mood swing, and fainting after 48 h of consumption (p < 0.05). | [ | |
| Anti-bronchitis | Humans | Whole plant extract | Dry powder extract | 160 mg oral dose along with 60 mg primrose ( | Placebo tablet without ingredients | Not defined | The extract reduced the cough symptoms on day 9 with an efficacy of 73.7% in comparison with placebo (day 11; 57.8%) (p < 0.0001). Reduction of bronchitis severity score was observed only after 4 days in case of extract (-6.2) in comparison with placebo (-4.1) (p < 0.05). The extract also reduced minor symptoms like disturbance in sleeping, rising body temperature, chest pain, and difficulty in breathing. | [ |